Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
Analysis
Comment
Deals
Events
News
People

Healthcare

Oxford Nanopore to embrace $2.1bn round
Amgen and Illumina-backed genetic sequencing technology developer Oxford Nanopore is reportedly eyeing a $2.1bn private placement.
Taimei takes $212m with Tencent's help
Tencent has led a series E-plus round for Taimei as part of a capital influx totalling $212m, with SoftBank's SBCVC unit also among the investors.
Corporate venturing deal net: 14-18 October 2019
Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
Tigermed and Temasek target $62m for health fund
Tigermed has put up $12m for biotech-oriented fund TG Sino-Dragon Fund, which is also backed by Temasek and which has set a $62m target for its final close.
Eli Lilly deems dMed worth it in $50m round
Clinical research partner dMed has completed a series B round that included returning investor Lilly Asia Ventures as it seeks to expand internationally.
Phathom measures out IPO terms
Takeda is set to emerge with almost 26% of Phathom Pharmaceuticals, which has licensed one of its gastrointestinal disease drugs, and which is targeting $158m.
Tela Bio tells of $69m IPO filing
ProMedica and Pacira are both in line for exits after surgical implant producer Tela Bio filed for an initial public offering.
Healx seals $56m series B
Intel Capital was among the participants in a round that lifted the total raised by rare disease-focused drug developer Healx to nearly $70m.

Other News

Abalos attracts series A attention
Boehringer Ingelheim Venture Fund co-led a $13.3m round for the immuno-oncoclogy startup, which was spun out of University of Duisburg-Essen’s and University of Düsseldorf.
Cyteir secures series B funding
The cancer therapy developer boosted a series B round led by Novo and backed by Celgene to $75.2m, with both corporates contributing to the latest tranche.
Sequis Life books $33m appointment with Alodokter
Sequis Life led a series C round for online healthcare and insurance portal Alodokter that included Philips and existing investor SoftBank Ventures Asia.
Ansun gets its hands on $80m
Lilly Asia Ventures returned for the respiratory disease drug developer's series B round, having co-led its $85m series A last year.
Parsley Health packs in $26m
The Chernin Group-backed personalised care provider plans to use the series B funding to expand into new cities and take its telemedicine offering nationwide.
Accolade recognises $20m investment
Humana provided $20m for healthcare assistance platform Accolade through the widening of a strategic agreement signed in March.

Editor's Picks

Vertex veers to Semma for $950m acquisition
Novartis, Medtronic and SinoPharm will exit the stem cell-based diabetes therapy developer in an acquisition by Vertex Pharmaceuticals.
Carroll retires from Lilly after two decades
After 22 years at Eli Lilly that included laying the groundwork for its corporate venturing activities, senior vice-president of corporate business development Darren Carroll is retiring.
BridgeBio crosses over to public markets with $349m
AIG scored an exit as genetic disease and cancer drug developer BridgeBio Pharma floated above its range while increasing the number of shares in its IPO.
test reg

Login